Illumina wins FDA approval for test to identify treatable cancers
The FDA has approved DNA sequencing giant Illumina’s cancer test that checks more than 500 genes in a tumor to potentially match patients with targeted therapies from Bayer or Eli Lilly. Illumina has...
View ArticleInvivyd says new Phase 3 data on Covid antibody support prophylactic use
Invivyd’s monoclonal antibody can cut the risk of contracting Covid-19 in both healthy and immunocompromised people, according to the latest exploratory analysis from a Phase 3 trial. The biotech’s...
View ArticleClik here to view.
Former Regenxbio leaders take rare disease gene therapies to startup with $15M
Two Regenxbio gene therapies are getting a second chance at newly-seeded startup Tern Therapeutics, which launched from stealth Tuesday with $15 million. In November, Regenxbio announced it was laying...
View ArticleRedalpine closes $200M fund; A base editing pact in China; Merck starts...
Plus, a Phase 3 fail from a small public company: Redalpine’s $200M fund: The nearly two-decade-old VC firm closed its sixth early-stage fund, dubbed RAC VII. The Zurich-based firm has invested in...
View ArticleClik here to view.
Once-promising cancer drugs appear to protect mice from Alzheimer’s
Drugs designed to help the immune system fight cancer might also stave off dementia, according to a study in mice. Researchers at Stanford University discovered a new role for the metabolic enzyme IDO1...
View ArticleDuality Biologics, an ADC partner of BeiGene and BioNTech, files for Hong...
Clinical-stage antibody-drug conjugate startup Duality Biologics has filed for an initial public offering in Hong Kong, where there have been only a handful of biotech listing debuts in recent...
View ArticleAstraZeneca pours $135M into boosting biologics capacity in Sweden
AstraZeneca is spending $135 million to expand a biologics facility in Sweden due to an increase in demand for its pre-filled syringe drug products, a company spokesperson told Endpoints News. The...
View ArticleEli Lilly releases single-dose vials of Zepbound at half the price of other...
Eli Lilly will begin selling single-dose vials of its drug tirzepatide, marketed as Zepbound for weight loss, and price them at least 50% lower than the list price of all other incretin medicines for...
View ArticleWidening GLP-1 coverage could cost Medicare almost $150B annually, study finds
As Congress considers widening Medicare’s coverage of the burgeoning class of weight loss medications, a new study says further expansion of eligible patients into new indications could cost a pretty...
View ArticleBiopharma companies, BARDA call for more clarity on FDA's new platform tech...
Following the FDA’s May release of long-awaited draft guidance explaining how companies can win designations for certain cell and gene therapy “platform” technologies, companies like Regeneron,...
View ArticleIpsen files another Onivyde lawsuit two weeks after receiving new patent
Two weeks after receiving a new patent on its pancreatic cancer treatment Onivyde, Ipsen has filed another lawsuit against a potential competitor. Ipsen argued on Friday that Conjupro Biotherapeutics’...
View ArticleClik here to view.
Pfizer partners with Flagship genetics startup Quotient on heart and kidney...
Pfizer has struck its second partnership with a Flagship Pioneering startup, working with Quotient Therapeutics to identify genetic mutations that arise by chance throughout life and make individual...
View ArticleClik here to view.
California Institute for Immunology and Immunotherapy gets $120M gift for...
Surgeon Gary Michelson and his wife Alya have donated $120 million to a Los Angeles-based public-private initiative focused on advancing research into immunology and vaccines. The Michelsons’ gift to...
View ArticleClik here to view.
Noetik raises $40M Series A to advance AI ambitions in cancer — with an...
After serving as Pfizer’s top lawyer and now chairing Alnylam’s board, Amy Schulman’s latest biotech bet could be seen as somewhat of a surprise. The managing partner of venture capital firm Polaris...
View ArticleClik here to view.
Bayer partners with RNA startup launched out of Dana-Farber
Even as Bayer continues cutting costs across its conglomerate, it’s still making some small R&D deals to add to its pipeline. On Wednesday, the German multinational pharma and NextRNA Therapeutics...
View ArticleClik here to view.
Neurocrine's schizophrenia data are good enough for Phase 3 — but maybe not...
Neurocrine Biosciences’ effort to chase down Bristol Myers Squibb and Karuna Therapeutics in schizophrenia just got more complicated. In a Phase 2 readout Wednesday morning, Neurocrine reported that...
View ArticleNovartis partners with small North Carolina biotech to make its biologics...
Novartis announced a collaboration on Wednesday with a small North Carolina biotech whose technology could help turn more of the Swiss pharma giant’s infused drugs into injections that patients can...
View ArticleNovartis seeks to expand Leqvio into heart disease prevention
Novartis announced Wednesday that Leqvio lowered bad cholesterol levels, compared with a placebo or the cholesterol-lowering drug ezetimibe, in patients at low-to-moderate risk of developing...
View ArticleSpringWorks gets priority review; Botox competitor data; Hyundai's Covid...
SpringWorks scores FDA priority review: The agency accepted mirdametinib’s new drug application and granted it a priority review for the treatment of adult and pediatric patients with neurofibromatosis...
View ArticleFDA warns EyePoint over eye implant manufacturing woes
The FDA has sent EyePoint Pharmaceuticals a warning letter after uncovering manufacturing issues with the company’s eye implant Yutiq. The letter, issued July 12 and published Tuesday, said FDA...
View Article